GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)
Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, Link T, Bjelic-Radisic V, Huober J, Untch M, Jackisch C, Solbach C, Blohmer JU, Rhiem K, Buechele T, Nekljudova V, Loi S (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: KARGER
City/Town: BASEL
Pages Range: 38-39
Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT
DOI: 10.1016/j.annonc.2022.07.235
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universität Witten/Herdecke
Germany (DE)
HELIOS Kliniken
Germany (DE)
Technische Universität Dresden
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Peter MacCallum Cancer Centre
Australia (AU)
Evangelische Kliniken Essen-Mitte
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Kantonsspital St.Gallen
Switzerland (CH)
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universität Witten/Herdecke
Germany (DE)
HELIOS Kliniken
Germany (DE)
Technische Universität Dresden
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Peter MacCallum Cancer Centre
Australia (AU)
Evangelische Kliniken Essen-Mitte
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Kantonsspital St.Gallen
Switzerland (CH)
How to cite
APA:
Loibl, S., Reinisch, M., Denkert, C., Schneeweiss, A., Seiler, S., Fasching, P.,... Loi, S. (2022). GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC). In ONCOLOGY RESEARCH AND TREATMENT (pp. 38-39). BASEL: KARGER.
MLA:
Loibl, Sibylle, et al. "GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2022. 38-39.
BibTeX: Download